MS State of the Art Symposium 2022

8th February 2022

Paediatric MS: What we know and what we still need to learn

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-07-20220207_Article3_3_Article3.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 8th February 2022 14th February 2022

The landscape of paediatric multiple sclerosis (MS) is rapidly evolving. In her presentation titled ‘Pediatric MS – Current treatment strategies and future directions’ at the MS State of the Art…

Samyuktha Pillai, PhD
0
0

7th February 2022

Multiple sclerosis management in the elderly

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-06-20220207_Article4_Article4.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 7th February 2022 14th February 2022

The life expectancy in multiple sclerosis (MS) continues to increase and is now comparable to that of the general population.1 This increase comes with the challenge of learning how to…

Samyuktha Pillai, PhD
0
0

3rd February 2022

Preliminary results from stem cell transplantation as an MS therapy in Switzerland

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-01-20220202_Article1.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 3rd February 2022 14th February 2022

Autologous hematopoietic stem cell transplantation (aHSCT) has been used in the treatment of multiple sclerosis (MS) since 1995 and was approved in Switzerland in June 2018. In their presentation ‘Stem…

Samyuktha Pillai, PhD
0
0

3rd February 2022

MS 2022: Upcoming therapies, and their pros and cons

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-01-20220202_Article2.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 3rd February 2022 14th February 2022

The repertoire of available multiple sclerosis (MS) disease modifying therapies (DMTs) is constantly growing. In recent years, there have been several new DMTs that have entered the market. In his…

Samyuktha Pillai, PhD
0
0